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Abstract: Clipping of recombinant proteins is a major issue in animal cell cultures. A recombinant
Fc-fusion protein, VEGFR1(D1–D3)-Fc expressed in CHOK1SV GS-KO cells was observed to be
undergoing clippings in lab scale cultures. Partial cleaving of expressed protein initiated early on
in cell culture and was observed to increase over time in culture and also on storage. In this study,
a few parameters were explored in a bid to inhibit clipping in the fusion protein The effects of culture
temperature, duration of culture, the addition of an anti-clumping agent, ferric citrate and use of
protease inhibitor cocktail on inhibition of proteolysis of the Fc fusion were studied. Lowering of
culture temperature from 37 to 30 ˝C alone appears to be the best solution for reducing protein
degradation from the quality, cost and regulatory points of view. The obtained Fc protein was
characterized and found to be in its stable folded state, exhibiting a high affinity for its ligand and
also biological and functional activities.
Keywords: Fc fusion protein; VEGFR1(D1–D3)-Fc; CHOK1SV GS-KO; clipping; proteolysis;
inhibition; stable; folded; biological activity
1. Introduction
Fusion proteins are generated by combining the genes encoding two or more proteins, where the
benefits of both the components are achieved [1]. Clinically and commercially, the most successful
fusion proteins to date are the Fc-fusion proteins. With six fusion proteins in different phases of clinical
trials, as of 2014, and several more in the pre-clinical pipeline, it is one of the most expanding and
important classes of molecules researchers are focusing on. Most protein drugs have a short serum
half-life of a few minutes to a few hours, as a result of large size and rapid renal clearance [2,3]. The Fc
region of a Fc-fusion protein confers additional pharmacokinetic (immunoglobulin-like) properties,
such as increasing the drug half-life due to interaction with the cellular Fc receptor (FcRn), and
serum stability of most biologically active proteins. On the other hand, the fusion partner of the Fc
domain imparts the therapeutic benefit of the protein. The sales of approved protein-based drugs in
2010 was approximately USD $108 billion [4], with half of it accounting for monoclonal antibodies
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and the remaining for Fc fusions, antibody conjugated drugs, bispecific antibodies, antigen-binding
antibody fragments, and other engineered therapeutic molecules. In fact, the total revenue generated
from therapeutic proteins, including monoclonal antibodies and fusion proteins, in the US is about
$64 billion [5]. Global sales for etanercept, the most commercially successful Fc-fusion was USD
$7.3 billion in 2010, which was better than that of the most successful IgGs, including bevacizumab
($6.9 billion), rituximab ($6.8 billion) or infliximab ($6.5 billion) [6]. In fact, in 2012, US sales for Fc
fusions grew at the highest rate for all bio-therapeutics in the USA, at an incredible ~35.3% (USD
$5.8 billion) [7]. There are 47 monoclonal antibodies and Mab-derived products that have been
approved in the USA or Europe as of 2014, with 44 being produced in mammalian cells. Of these,
10 belong to the class of Fc fusion proteins. In order to support the ever-increasing need for highly
potent bio-therapeutics, the requirement of high drug dosages and manage the cost of production, the
biotech and biopharmaceutical industry is constantly improving in productivity of complex therapeutic
proteins. The global sale for fusion proteins is predicted to rise to $10.1 billion on a risk-adjusted basis
by 2016 [8].
Proteins produced in bacterial and mammalian host cells by recombinant DNA technology
often are fully or partially degraded in culture. This poses a major challenge to biotech industry [9],
where efficiency and high productivity are required at lower costs. There are several reasons for low
production of recombinant proteins, most of which have diagnostic and therapeutic applications.
Some of these are loss of gene expression due to structural changes in the recombinant gene,
loss of a gene from a plasmid, loss of plasmid, instability of plasmid (structural, segregational,
multimerization) and metabolic pressure on host cells resulting in toxic metabolite accumulation
and oxygen depletion. Moreover, inefficient chromosomal integration, protein aggregation, protein
misfolding, improper cleavage of signal peptide and action of host cell-related proteases are common
problems encountered in mammalian cell cultures for the production of recombinant proteins.
Degradation of recombinant proteins in culture is a common and serious problem [10,11].
Degradation of most proteins, including recombinant monoclonal antibodies and fusion proteins, may
be attributed to host cell-derived proteases, which may be very site specific or have a broad substrate
range. The most common strategies adopted to control proteolysis are engineering host cell lines
by making them protease-negative or mutants for intracellular protease expression and for efficient
post-translational modification and secretion. Some other methods used are genetic engineering, by
mutating known protease sites in transfecting gene of interest, isolating and analyzing the type of
protease secreted by CHO cells and inhibiting specifically, media optimization [12], lowering culture
temperature [12–14], use of protease inhibitors and early product harvesting as lysis of non-viable cells
in culture releases proteases which accumulate over time and degrade the desired product.
Proteolytic activity in supernatants of CHO cell cultures might be characterized using zymography
or protease screening with various substrates, or by shotgun proteomics as a measure to improve the
quality of recombinant proteins produced by CHO and CHO-derived cultures. In fact, the heterogeneity
of recombinant glycoproteins produced in CHO culture may be attributed to modifications as
a result of the action of proteases secreted by CHO. It has been earlier shown by Sandberg et al.
that matrix metalloproteases (MMPs), including MMP3, MMP10, and MMP12, as well as their
autoproteolytic smaller products, are secreted by CHO cell line during the production of recombinant
factor VIII [15]. Similarly, DHFR-deficient CHO cells have been found to continuously secrete cysteine
endopeptidases [16]. Serine proteases aprotinin and AEBSF (4-(2-Aminoethyl) benzene sulfonyl
fluoride hydrochloride) have been shown to largely inhibit proteolytic activity in CHO cells producing
gp120 protein The addition of iron citrate in CHO culture producing IFN-γ seemed to inhibit proteolysis
of final product, suggesting the presence of metalloproteases in culture [17].
In our laboratory, a soluble anti-VEGF molecule, VEGFR1(D1–D3)-IgGFc fusion protein that was
being cloned and developed in mammalian CHOK1SV GS-KO system, appeared to be undergoing
clipping upon expression in culture. VEGFR1(D1–D3)-Fc is a fusion protein containing extracellular
domains 1, 2 and 3 of human VEGF receptor 1 fused to Fc region of antibody IgG1. The fusion protein
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acts as a decoy receptor by binding to and neutralizing cellular growth factor, VEGF. This makes VEGF
unavailable to its major cellular receptor VEGFR2 inhibiting downstream signaling processes ultimately
leading to inhibition of cell growth, proliferation, migration, and tube formation. The clipping
of the protein in culture was evident from the SDS-PAGE and Western blot analysis of the cell
culture supernatants collected over all days in culture at all stages. In the present study, we have
shown different ways of minimizing degradation in VEGFR1(D1–D3)-Fc fusion protein in lab scale
experiments. Once proteolysis was under control, the highest yielding clone, P8D6, was taken to
the roller bottle stage and, subsequently, to a bioreactor for protein production. The ligand-binding
efficacy, characterization, stability and functional activity of the protein were also studied and the
protein was found to be stable and functionally active.
2. Results
2.1. Generation of Fc-Fusion Protein
The VEGFR1(D1–D3)-Fc gene was generated by fusing the first three domains (D1, D2 and D3) of
VEGFR1 gene from a VEGFR1 clone to the Fc (CH2–CH3) region of IgG1 of a monoclonal antibody
clone already existing in our laboratory. Multiple overlap polymerase chain reactions were used to
generate the fusion gene, followed by cloning the gene in mammalian expression vector, pXC17.4,
and transfecting CHOK1SV GS-KO cells for generation of stable clones. The amino acid sequence of
VEGFR1(D1–D3)-Fc protein is given below:
MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAA
HKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKK
KETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDG
KRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLL
RGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKM
QNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFIDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK
Amino acid positions:
Signal sequence (1–26)
VEGFR1 domain D1 (32–123)
VEGFR1 domain D2 (151–214)
VEGFR1 domain D3 (230–327)
IgG1 Fc CH2 domain (342–454)
IgG1 Fc CH3 domain (455–561)
There are six sites for N-glycan attachment in the molecule at N (asp) shown in bold and
underlined in the text, at amino acid positions:
VEGFR1(D1): 100
VEGFR1(D2): 164, 196
VEGFR1(D3): 251, 323
IgG1-Fc (CH2): 411
2.2. Protein Clipping in Different Host Cells
Supernatants from transfected HEK293T cells in 24-well plate were collected after different time
points (6, 24, 48, 72 and 120 h) and protein expression checked by Western blot under reducing
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conditions (Figure 1a). Similarly, supernatants from multiple clones of CHOK1SV GS-KO at various
clone development stages were analyzed by Western blot for presence of expressed VEGFR1(D1–D3)-Fc
protein (Figure 1b–d).
It is clearly evident from the Western blots performed under reducing conditions that VEGFR1
(D1-D3)-Fc is being clipped immediately after expression from both host cell lines. Cleavage of this Fc
protein is probably independent of host cell.
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protein expression analysis. 
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Two different CHOK1SV GS-KO clones for VEGFR1(D1–D3)-Fc, clone P8D6 and clone 2 were 
cultured in T-25 flasks in CDCHO media at 37 °C and 5% CO2 in presence and absence of ferric 
citrate as a prospective proteolysis inhibitor. Protein degradation pattern was not identical in the 
clones suggesting that proteolysis is clone specific (Figure 2a). Lanes 9 and 10 show different profiles 
of two clones on day 3 growing at 37 °C in culture medium containing no proteolytic inhibitors. The 
difference in the degree of proteolysis is that different clones may be attributed to their protein 
expressing ability as well. 
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2.3. Clone Specific Protein Degradation
Two different CHOK1SV GS-KO clones for VEGFR1(D1–D3)-Fc, clon P8D6 and cl ne 2 were
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Figure 2. (a) Western Blot for VEGFR1(D1–D3)-Fc expression with and without 10ˆ ferric citrate
in culture supernatant for two different clones; (b) Western Blot for VEGFR1(D1-D3)-Fc expression
with and without 10ˆ ferric citrate in culture; (c) effect of ferric citrate on reduction of proteolysis in
VEGFR1(D1-D3)-Fc at 37 ˝C; (d) effect of ferric citrate on reduction of proteolysis in VEGFR1(D1-D3)-Fc
at 30 ˝C.
Int. J. Mol. Sci. 2016, 17, 913 7 of 22
2.4. Protease Inhibition Assays
2.4.1. Lowering of Culture Temperature
It was observed that maintaining the culture at 30 ˝C, significantly reduces degradation of the
protein expressed, even though productivity and cell growth decreases to a large extent. The proteolysis
inhibitory effect of lower culture temperature is further enhanced by the addition of inhibitors of
protein degradation to the cell culture. Culturing cells at a lower temperature (30 ˝C) effectively reduces
proteolysis to a large extent, as is evident from Western blots (Figure 2c,d). Lane number 2 from blots
clearly show that the clipped product of VEGFR1(D1–D3)-Fc (40 kDa protein) at 37 ˝C is more than
the intact protein (78 kDa), whereas, at 30 ˝C, the scenario is reversed. Upon inclusion of protease
inhibitors at low temperatures, protein degradation is further arrested (Figure 3a,b). Culturing cells
at a lower temperature also prolongs cell viability over time, even though total protein productivity
is compromised. Cell viability at day 8 in culture at 30 ˝C is almost 90%, whereas it is about 70% for
culture grown at 37 ˝C (Supplementary Figure S1). This degradation process progresses with a number
of days in culture.
2.4.2. Addition of Ferric Citrate
Two VEGFR1-Fc clones (clones 2 and P8D6) were cultured in the presence of 10ˆ ferric citrate
in CDCHO media at 37 ˝C and 5% CO2. Western blots were performed with culture supernatants
collected on different days and checked for degradation profile of protein in presence and absence of
inhibitor for both clones (Figure 2b). The effect of a higher concentration of ferric citrate (120ˆ) and at
a lower culture temperature was even more pronounced (Lane 10; Figure 2c,d).
2.4.3. Addition of Protease Inhibitor Cocktail
The P8D6 cultures were grown in the presence of protease inhibitor cocktail at 37 and 30 ˝C in
order to study the individual as well as additive effect of cocktail inhibitors with low temperature,
if any, on proteolysis inhibition. It was observed, as of day 12, that culturing cells alone at 30 ˝C
definitely reduced protein clipping relative to 37 ˝C (Lane 6; Figure 3a,b) and addition of protease
inhibitor cocktail further prevented the degradation process (Lane 7; Figure 3a,b).
Int. J. Mol. Sci. 2016, 17, 913 7 of 22 
 
2.4. Protease Inhibition Assays 
2.4.1. Lowering of Culture Temperature 
It was obser d t at maintaining the culture at 30 °C, significantly reduces d gradation of the 
pro ein xpressed, even though productivity and cell growth decreases to a large extent. The 
proteolysis inhibi ry ff ct of lower culture temperature is further enhanced by the addition of 
inhibitors of prot in d gradation to the cell cultur . Culturing cells at a lower temperature (30 °C) 
effectively reduces proteolysis to a large extent, as is evident from Western blots (Figure 2c,d). Lane 
number 2 from blots clearly show that the clipped product of VEGFR1(D1–D3)-Fc (40 kDa protein) 
at 37 °C is more than the intact protein (78 kDa), whereas, at 30 °C, the scenario is reversed. Upon 
inclusion of protease inhibitors at low temperatures, protein degradation is further arrested  
(Figure 3a,b). Culturing cells at a lower temperature also prolongs cell viability over time, even 
though total protein productivity is compromised. Cell viability at day 8 in culture at 30 °C is almost 
90%, whereas it is about 70% for culture grown at 37 °C (Supplementary Figure S1). This 
degradation process progresses with a number of days in culture. 
2.4.2. Addition of Ferric Citrate 
Two VEGFR1-Fc clones (clones 2 and P8D6) were cultured in the presence of 10× ferric citrate in 
CDCHO media at 37 °C and 5% CO2. Western blots were performed with culture supernatants 
collected on different days and checked for degradation profile of protein in presence and absence of 
inhibitor for both clones (Figure 2b). The effect of a higher concentration of ferric citrate (120×) and at 
a lower culture temperature was even more pronounced (Lane 10; Figure 2c,d). 
2.4.3. Addition of Protease Inhibitor Cocktail 
The P8D6 cultures were grown in the presence of protease inhibitor cocktail at 37 and 30 °C in 
order to study the individual as ell as additive effect of cocktail inhibitors with low temperature, if 
any, on proteolysis inhibition. It was observed, as of day 12, that culturing cells alone at 30 °C 
definitely reduced protein cli ping relative to 3  °  (  ; Figure 3a,b) and ad ition of protease 
inhibitor ocktail further prevented the degradatio    7; Figure 3a,b). 
(a)
Figure 3. Cont. Figure 3. Cont.
Int. J. Mol. Sci. 2016, 17, 913 8 of 22
Int. J. Mol. Sci. 2016, 17, 913 8 of 22 
 
(b)
Figure 3. (a) Effect of protease inhibitor cocktail on reduction of proteolysis in VEGFR1-Fc at 37 °C; 
(b) effect of protease inhibitor cocktail on reduction of proteolysis in VEGFR1(D1–D3)-Fc at 30 °C. 
2.5. Scale-up Production of VEGFR1(D1–D3)-Fc in Bioreactor 
Once it was observed that proteolysis of the molecule can be reduced at a low culture 
temperature, addition of ferric citrate or protease inhibitor cocktail and harvesting at an earlier time, 
the highest VEGFR1(D1–D3)-Fc yielding clone, P8D6 was cultured at 30 °C in a 4-L bioreactor in 
fed-batch mode and harvested on day 8. SDS-PAGE and Western blots were used to analyze 
supernatants for profiling of expressed protein (Figure 4a–c). The protein was purified using Protein 
A affinity chromatography followed by SP-sepharose strong cation exchange chromatography. The 
purified fractions eluted from the ion-exchange chromatographic column were analyzed by Western 
blot (Figure 4d) before pooling and concentrating in the appropriate buffer for further analyses. It is 
evident from SDS-PAGE and Western blot of culture supernatants, and of purified protein, that the 
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2.5. Scale-up Production of VEGFR1(D1–D3)-Fc in Bioreactor
Once it was observed that proteolysis of the molecule can be reduced at a low culture temperature,
addition of ferric citrate or protease inhibitor cocktail and harvesting at an earlier time, the highest
VEGFR1(D1–D3)-Fc yielding clone, P8D6 was cultured at 30 ˝C in a 4-L bioreactor in fed-batch mode
and harvested on day 8. SDS-PAGE and Western blots were used to analyze supernatants for profiling
of expressed protein (Figure 4a–c). The protein was purified using Protein A affinity chromatography
followe by SP-sepharose strong cation exchange chromatography. The purified fractions eluted from
the ion-exchange chromat graphic colum were a alyzed by West rn blot (Fig e 4d) befor pooling
and co centrating in the ppropriate buffer for f ther analyses. It is evident from SDS-PAGE and
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The purified protein was concentrated to 10 µg using Amicon®Ultra-4, Ultracel 30k filter 
(Millipore; catalogue # UFC803096; Lot # R6SN15198, Billerica, MA, USA) before being loaded onto 
an analytical RP-HPLC column (Figure 5a). Four peaks were eluted from the run and individually 
collected. Peak 3’s fraction was dried under vacuum and characterized by mass spectrometry. 
Figure 4. (a) SDS-PAGE of supernatant samples of bioreactor culture on various days (non-reduced);
(b) SDS-PAGE of supernatant samples of bioreactor culture on various days (reduced); (c) Western blot
of samples from bioreactor (reduced); (d) Western Blot of VEGFR1(D1–D3)-Fc purified fractions from
SP-Sepharose cation exchange chromatography (reduced samples).
2.6. RP-HPLC
The urified protein was concen rated to 0 µg us ng Amicon®Ultra-4, Ultracel 30k filter
(Millipore; catalogue # UFC803096; Lot # R6SN15198, Billerica, MA, USA) before being loaded onto
an analytical RP-HPLC column (Figure 5a). Four peaks were eluted fro the run and individually
collected. Peak 3’s fraction was dried under vacuum and characterized by mass spectrometry.
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2.8. Fluorescence Spectroscopy
Total fluorescence of a protein is a mixture of the fluorescence from individual aromatic residues.
The two amino acids that fluoresce are tryptophan (excitation maximum at ~280 nm) and tyrosine
(excitation maximum at ~276 nm). Tryptophan (Trp), with a much larger extinction coefficient and
fluorescence quantum yield, is the most prominent emitter [19]. In general, the more buried these
residues are within the protein the less fluorescence quenching the more they will experience, including
a reduced solvent induced fluorescence quenching. Fluorescence intensity of a protein can either
increase or decrease during folding, with tryptophan fluorescence often used as a means of determining
both stability and folding of a protein.
The fluorescence data indicates reasonable tertiary structure of the protein as the chromophores
show strong emission at 330 nm. Both Trp and tyrosine (Tyr) have a wavelength of maximum
absorption at around 280 nm, but at 295 nm, only Trp gets excited and not the weaker Tyr. Emission
peak of Trp ranges from 300 to 350 nm depending on the polarity of the solvent. In Figure 5c,
wavelength excitation maximum is ~330 nm, which shows good folding of the protein suggesting
tryptophan moieties deeply buried within the protein without getting exposed to local environment
consisting of solvent, denaturants, surfactants and presence of nearby protonated amino acid residues,
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thus minimizing fluorescence quenching. Overall, the fluorescence data indicate intact tertiary
structure of VEGFR1(D1–D3)-Fc.
2.9. Circular Dichroism
CD is a valuable spectroscopy technique for examining the secondary structure and protein
folding in a wide range of wavelengths [20]. It also studies the conformational stability of a protein in
solution. One of the strengths of CD is that various aspects of protein structure can be determined.
In the far UV, the peptide bond is the principal absorbing group; studies in this region can give
information on the secondary structure. In the near UV, the aromatic amino acid side chains (Phe, Tyr,
Trp) absorb in the range 250 to 290 nm. The tertiary folding of the polypeptide chain can place these
side chains in chiral environments, thus, giving rise to CD spectra, which can serve as characteristic
fingerprints of the native structure.
The far-UV CD data clearly show good secondary structures. (Figure 5d) The raw data was
deconvoluted using BeStSel (beta structure selector) online platform [21] to assess the percentage of
secondary structure elements predicted α-helix at 9.5% and β-strand at 33% (antiparallel: 33% and
parallel: 33.5%).
2.10. Size Exclusion Chromatography
SEC data implies the presence of 87.22% of an intact protein, along with 7.78% of high molecular
weight aggregates and about 5% low molecular weight impurities in the form of degraded products.
2.11. Protein Stability Determination
Stability of protein samples stored at different temperature conditions (´70, ´20, 2–8, 25, and
40 ˝C) was determined at various time points (0 day, 15 days, 1 month, 3 months and 6 months)
by SDS-PAGE, Western blot and RP-HPLC. Data after 6 months show that the protein is stable at
´70 ˝C and ´20 ˝C, whereas it starts progressively degrading at higher temperatures beyond this
time (Figure 5f). Since the SDS-PAGE and RP-HPLC profiles after the second month suggest complete
degradation of the protein at 40 ˝C, this temperature was not studied for further time points. With the
increase in storage temperature, the amount of cleaved products represented as low molecular weight
impurities increases considerably.
2.12. Ligand-Binding Affinity of VEGFR1(D1–D3)-Fc by ELISA
The affinity of VEGFR1(D1–D3)-Fc protein towards its ligands, VEGF165 and VEGF121 was checked
using ELISA and compared to the affinity of another fusion protein, VEGF TrapR1R2 towards the same
ligands (Figure 6). It was observed that VEGFR1(D1–D3)-Fc exhibits a strong affinity towards its
natural ligands, and its affinity towards both the VEGF ligands was almost comparable to that of
a known decoy receptor trap, aflibercept.
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Figure 6. Binding efficiency comparison of VEGFR1(D1–D3)-Fc and aflibercept to VEGF isoforms
by ELISA.
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2.13. Inhibition of Endothelial Cell Proliferation by VEGFR1(D1–D3)-Fc
Inhibition of proliferation was demonstrated in a HUVEC proliferation assay using Alamar Blue
fluorescence as indicator. Viability was assessed by reduction of Alamar Blue, which was measured
spectrophotometrically at 544/590 nm. VEGFR1(D1–D3)-Fc shows reduction of VEGF-stimulated cell
proliferation with increasing concentration of the inhibitor (Figure 7a).
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2.14. Inhibition of Endothelial Tube Formation by VEGFR1(D1-D3)-Fc
VEGFR1(D1–D3)-Fc protein was used to check its inhibitory activity on network formation by
endothelial cells. Images were taken with a digital camera fitted to an inverted microscope under 5ˆ
magnification (Figure 7b,c).
3. Discussion
We investigated the effects of different culture parameters like culture temperature, culture
duration, and chemical inhibitor supplementation on protease activity in CHOK1SV GS-KO culture
expressing recombinant Fc fusion protein, VEGFR1(D1–D3)-Fc.
VEGFR1(D1–D3)-Fc protein was expressed i tw host cell , HEK293T and CHOK1SV GS-KO.
Recombinant protein expression levels were checked using Western Blot for VEGFR1-Fc in the cell
culture supernatants of transfected cultures. Protein expressed from both mammalian host cell lines
was clippe as detected by Western blots. Hence, host specific cleavag of the recombinant protein is
not evident from this study. Further, upon checking degradation pattern of the same protein in two
different CHOK1SV GS-KO clones (clone#P8D6 and clone#2), it was observed that the degradation
patterns were similar in both clones. However, the amount of degradation was varying which might
be dependent on the levels of productivity of the clones. This clone-to-clone variation, with respect to
the susceptibility of expressed proteins to proteases, might be because CHO is not a clonal cell line
due to the dynamic nature of its functional genome and potential to evolve [22]. Cell viability and cell
count patterns for both clones are different over days in culture (Supplementary Figures S2 and S3).
Several studies have shown that the degree of glycosylation of a glycosylated protein is directly related
to the susceptibility to proteases with the presence of more glycan moieties, reducing accessibility of
proteases to proteolytic cleavage sites in proteins [10,23]
Proteolysis can also occur as a result of lysis of non-viable cells, which release proteases in the
medium, which in turn is responsible for the degradation of the product. One way to minimize this
process is by reducing the clumping of cells in culture. When clumping or aggregation occurs, the
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overall surface area exposed to available medium is reduced resulting in reduced growth rate, cell
densities, and productivity. Additionally, cells in the middle of a large clump are more prone to the
stress of limiting nutrients and toxic build-up leading to programmed cell death/apoptosis, followed
by lysis and protease release. Iron is essential for cell respiration and metabolism and protects cells
from oxidative damage. Ferric citrate is a soluble iron source for serum-free medium. It has been
previously shown to inhibit metalloproteases, probably by blocking zinc atoms in the catalytic domain
of the enzymes [17]. Rosenmund et al. have also shown that, in physiological conditions, serine
proteases are susceptible to nontransferrin-bound Fe3+ [24]. Upon addition of ferric citrate to cell
culture at a concentration of 10ˆ, it was observed that cell count and viability for clone P8D6, increased
with days in culture at 37 ˝C as compared to control (Supplementary Figure S4). The addition of
protease inhibitor cocktail (serine and cysteine proteases inhibitors) to culture, increased cell viability
with increased number of days in culture, as compared to control without inhibitor (25% vs. 76% on
day 12).
It has been already reported that lowering of culture incubation temperatures from 37 to 34, 33, or
even 28 ˝C, increases the product quality in terms of reducing clipping of protein [25,26]. At a culture
temperature of 30 ˝C, although growth of cells was suppressed, cell viability remained high for a
prolonged period of time.
As part of validation, a large-scale production of VEGFR1-Fc was carried out in a 4-L bioreactor
in a fed-batch mode. VEGFR1(D2–D3)-Fc producing clone P8D6 was cultured in a roller bottle at 37 ˝C
until a one-liter inoculum was ready to be seeded in a bioreactor containing 4 L of CDCHO medium.
During inoculum preparation in roller bottles, ferric citrate (12ˆ) was added to the culture medium in
an attempt to have a minimum amount of carry over clipped species in the bioreactor. No additives in
the form of protease inhibitors were added to the bioreactor, as it would have later implications from a
regulatory point of view during large-scale production. Under fed-batch mode of culture, the cells
were grown in the bioreactor at 30 ˝C for 8 days, and supernatants were analyzed every day using
SDS-PAGE and Western blots. Reduction in the levels of protein degradation was observed. Since the
stability of the expressed Fc-fusion protein appeared to decrease with time in culture, the culture
was harvested at an earlier time point to ensure minimum proteolysis. Protein A chromatography of
VEGFR1(D1–D3)-Fc from harvest resulted in a purified protein, which contained clipped species along
with the intact protein. The final purified protein, upon analysis by size exclusion chromatography,
showed a purity of above 87%. Degraded low molecular weight species constituted 5% of total protein
and about 8% formed high molecular weight aggregates. However, in spite of cleaved nature of the
protein, ELISA studies confirmed significant binding affinity towards ligands, VEGF165 and VEGF121
compared to a known VEGF receptor-Fc fusion protein, aflibercept. Analytical RP-HPLC data for the
purified protein showed four peaks, of which the major peak was analyzed by mass spectrometry and
found to be one of the glycosylated forms of VEGFR1(D1–D3)-Fc. Circular dichroism and fluorescence
data suggested that the protein was in a properly folded form with intact secondary and tertiary
structures and overall three-dimensional stability. The secondary structure consisted of about 50%
alpha helix and 10% beta sheets for the protein as predicted by CD. The intrinsic fluorescence of the
protein results in strong chromophore emission at 330 nm and minimal fluorescence quenching, which
predicts properly the folded stable tertiary structure of the protein. Stability studies of the protein
suggested that the protein is stable at ´20 ˝C and ´70 ˝C for a six month period, as is evident from
RP-HPLC profiles at various time points and at different temperature conditions. The protein was
also shown to be biologically active, as was evident from its ability to inhibit both endothelial cell
proliferation, as well as endothelial tube formation in HUVEC in vitro assays.
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4. Materials and Methods
4.1. Cell Culture
CHOK1SV GS-KO (Lonza Biologics, Slough, Berkshire, UK) was the mammalian cell line used
for producing VEGFR1(D1–D3)-Fc protein in culture. Cells were cultured in CDCHO proprietary
chemically defined medium (Gibco, Santa Clara, CA, USA). For stable transfection, cells and 50 µg
of linearized plasmid (pXC17.4 vector containing the gene of interest VEGFR1-Fc) were transferred
to a 0.4 cm Biorad cuvette and electroporated using a Bio-Rad GenePulser instrument (Hercules,
CA, USA) set at 0.298 kV and 900 µF with a time constant of 18.6 ms. All stable recombinant
protein-producing clones using glutamine synthetase (GS) knock out (KO) system was cultured
in plain CDCHO medium without glutamine or methionine sulfoximine (MSX). Clones were passaged
from 96-well plate to 24-well plate followed by sequential transfer to a T-25, T-75, T-175 flask and
a roller bottle at a density of 2 ˆ 105 cells/mL in each sub-culturing stage.
4.1.1. Different Host Cells
It is known that one of the reasons for clipping of Fc fusion proteins is a result of the action
of proteases secreted by host cells harboring the gene of interest [5]. In order to find out whether
proteolysis is dependent on the type of host cell, VEGFR1(D1–D3)-Fc recombinant gene was transfected
in two different mammalian cell lines, HEK293T, and CHOK1SV GS-KO. HEK293T cells were
transiently transfected with a plasmid containing VEGFR1(D1–D3)-Fc using lipofectamine™ 2000 (Life
Technologies, Carlsbad, CA, USA) as the transfection agent, whereas CHOK1SV GS-KO cells were
stably transfected by electroporation. VEGFR1(D1–D3)-Fc yielding CHOK1SV GS-KO clones were
propagated through various stages of development by passaging from 96-well plate through a 24-well
plate, T-25, T-75, T-175 flasks and a roller bottle. Western blot analyses were performed at every stage
of clone development in order to check for expression levels of the protein under both reducing and
non-reducing conditions (Figure 1a–d).
4.1.2. Different Clones Expressing Same Protein
Two different clones (clone P8D6 and clone 2) both expressing VEGFR1-Fc protein, were cultured
in CDCHO media at 37 ˝C. Expression of protein in cell culture supernatant for both clones on different
days in culture was compared by Western Blot (Figure 2a). The clones were cultured in the presence
and absence of anti-clumping agent ferric citrate as a proteolysis inhibitor.
4.2. SDS-PAGE and Western Blot
Culture supernatants at all stages of clone development (24 well plates, T-25, T-75, T-175 and
roller bottle, bioreactor) were analyzed for expression of VEGFR1(D1–D3)-Fc protein by Western Blot
under reducing and non-reducing conditions. Samples were resolved on 8%–10% polyacrylamide
gels in parallel to molecular weight marker (high range rainbow marker, Amersham, GE Healthcare).
Samples were reduced using β-mercaptoethanol and heat-denaturation prior to loading. Following
electrophoresis, gels were transferred to nitrocellulose membrane by passive blotting, and protein
was detected using HRP-conjugated goat anti-human IgG-Fc-γ specific polyclonal antibody (Catalog
#109-036-098; Jackson Immuno Research Labs Inc., West Grove, PA, USA) and developed by DAB-urea
(SigmaFast™ DAB (3,31-Diaminobenzidine tetrahydrochloride) with Metal Enhancer-Urea hydrogen
peroxide tablet, St. Louis, MO, USA) substrate solution.
4.3. Protease Inhibition Assays
4.3.1. Temperature
CHOK1SV GSKO culture expressing VEGFR1(D1–D3)-Fc was incubated at 37 and 30 ˝C in T-175
flasks in a 5% CO2 incubator. Degree of proteolysis was monitored until day 11 in culture using
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Western Blot. The effect of low temperature (30 ˝C) in presence of protease inhibitors was also studied
at the T-175 stage. The effect of temperature on cell growth was assessed by cell counting and cell
viability check and protein expression levels were analyzed by Western Blot of culture supernatants.
4.3.2. Ferric Citrate
Ferric citrate is used as an anti-clumping agent for reducing CHO cell aggregation in culture. It is
also known to inhibit metalloproteases and serine proteases present in the culture [24]. Ferric citrate
(anti-clumping agent B, Lonza, Slough, Berkshire, UK) at concentrations of 10ˆ, 12ˆ and 120ˆwere
used in CDCHO media as an inhibitor of proteolysis, while culturing cells at both 30 and 37 ˝C.
It is a proprietary formulation and comes as a 1000ˆ concentration, which we have diluted according
to our experimental needs. Cell counts on regular intervals were taken to check for cell growth and
productivity was analyzed by Western Blot of culture supernatants. The effect of 10ˆ ferric citrate
was first studied at 37 ˝C at the T-25 flask stage over a period of 10 days in culture for two different
VEGFR1-Fc clones. Next, the effect of ferric citrate at concentrations of 12ˆ and 120ˆwas studied at
both temperatures (37 and 30 ˝C) in T-175 flasks over a period of 11 days.
4.3.3. Protease Inhibitor Cocktail
Effect of protease inhibitor cocktail (cOmplete EDTA-free protease inhibitor cocktail tablet, Roche,
catalog# 11 873 580 001) on VEGFR1(D1-D3)-Fc protein clipping was studied at two incubation
temperatures of 37 and 30 ˝C. CHOK1SV GSKO clones were seeded at a density of 2 ˆ 105 cells/mL
in T-175 flasks and grown for 12 days in the presence of inhibitors, which completely inhibits serine
and cysteine proteases. Cell counts and viability were checked at regular time points and inhibition of
protein clipping was analyzed using Western Blot.
4.4. RP-HPLC
The highest protein-yielding clone was cultured in 4-liter fed-batch mode and purified by
Protein A affinity chromatography and strong cation exchange chromatography followed by analysis
of purified protein by RP-HPLC. RP-HPLC was performed with elution fractions on an analytical C5
column with dimensions of 150 mm ˆ 4.6 mm (Discovery Bio Wide, Supelco; Pore 5 µm; Catalog #
568422-U, Bellefonte, PA, USA) using mobile phase buffer A as 0.1% TFA in water and buffer B as 0.1%
TFA in 90% acetonitrile in water. The column temperature was 60 ˝C and a flow rate of 1 mL per min
was used to resolve proteins under the non-denaturing condition and detected by a two point UV
detector at 214 nm.
4.5. Mass Spectrometry
Peak fractions obtained from RP-HPLC run were collected separately. The major peak, peak 3 was
dried under vacuum and sent to Centre for Cellular and Molecular Platforms (C-CAMP), Bangalore, for
the intact mass analysis. Myoglobin was used for calibration. The samples were analyzed on ABSCIEX
MALDI-TOF 5800 (Framingham, MA, USA). All the samples are desalted and buffer exchanged in
50 mM ammonium bicarbonate of pH 7.5 by centrifugal ultrafiltration (Amicon Ultra-0.5 mL, 10 K
MWCO, 14,000 g, 15 min, 4C, Billerica, MA, USA). Five microliters of 10 mg/mL of sinapinic acid was
mixed with 5 µL of 1 mg/mL sample. One microliter of the sample was spotted on the plate and after
drying the sample was used for MALDI-TOF analysis.
4.6. Fluorescence Spectroscopy
Purified protein was diluted to 1:3 times with 5 mM phosphate buffer, pH 7.0, making a final
volume of 800 µL. The protein was analyzed on FP-8000 (Jasco, Easton, MD, USA). 10 µM protein was
used for analysis using a path length of 10 mm.
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4.7. Circular Dichroism
Stability and integrity of protein was analyzed by CD on J-710 (Jasco). The protein sample was
diluted to 1:1 with 400 µL of 5 mM phosphate buffer pH 7.0. For data acquisition, a path length and
data pitch of 1 nm each was used, with a bandwidth of 2 nm, response time of 4 s and scanning speed
of 50 nm/min for 2 accumulations. For far UV CD spectrum, 5 µM of protein was analyzed.
4.8. Size Exclusion Chromatography
The overall molecular size and the presence of aggregated species and low molecular weight
impurities were determined by Size-Exclusion HPLC analysis. SEC-HPLC chromatograms of VEGFR1
(D1–D3)-Fc are shown in the Figure 5e. An analytical gel filtration chromatographic column, TSK
column was used for testing: Tosoh-Gel, G-3000 SWXL (TOSOH; catalogue number 08541, Tokyo,
Japan); 7.8 mm internal diameter; 30 cm length; 5 micron particle size; 250˝ pore size. A total of 15 µg
of protein was injected onto the column. Mobile phase used was 20 mM phosphate buffer containing
400 mM sodium chloride, pH 7.0. Flow rate was 0.5 mL/min a run time was 35 min with a UV detector
(Tosoh, Tokyo, Japan) at 214 nm wavelength.
4.9. Protein Stability Determination
To determine the stability of VEGFR1(D1–D3)-Fc in vitro, purified VEGFR1(D1–D3)-Fc protein
(1 mg) was aliquoted in glass vials (1 mL per vial) and kept in stability chambers of varying temperature
conditions (´70 ˝C, ´20 ˝C, 2–8 ˝C, 25 ˝C and 40 ˝C) and analyzed at different time points (0 day,
15 days, 1 month, 2 months, 3 months and 6 months) using SDS-PAGE, Western blotting and
RP-HPLC profiling.
4.10. Detection of Ligand-Binding Affinity
An ELISA-based method was used to determine the binding affinity of VEGFR1(D1–D3)-Fc
to its common physiological VEGF ligands, isoforms VEGF121 and VEGF165. A micro-titer plate
(Nunc maxisorp) was coated with VEGF165 (conc. 3.3 mg/mL) and VEGF121 (conc. 0.9 mg/mL)
at a concentration of 250 ng/100 µL/well and coating was allowed to take place at 4 ˝C, overnight,
following which the plate was washed one time with 1ˆ PBS (300 µL/well). Contents from the plate
were flicked off and 300 µL of 1% BSA in 1X PBST was added to each well and blocking allowed to take
place for one hour at 37 ˝C. Dilutions of test sample {VEGFR1(D1–D3)-Fc} were prepared in 0.1% BSA
in 1ˆ PBST (0.05% PBST) in the range of 200 to 1.5 ng/mL. Aflibercept, used as a positive control, was
similarly diluted. The plate was washed three times with 300 µL of wash buffer (0.05% PBST) per well.
Standard dilutions and test samples were added to respective wells of the plate and plate incubated
at 37 ˝C for 1 h. The plate was again washed three times with wash buffer as before. Next, goat
anti-human IgG-Fc (Jackson; Cat#109-036-098) specific horse radish peroxidase labeled secondary
antibody at 1:40,000 dilutions (in 0.1% BSA in 1ˆ PBST) were added to each well and incubated at
370C for one hour. This was followed by three washes with 0.05% PBST. Finally 100 µL of 1ˆ TMB
substrate were added to each well and plate incubated in dark for 30 min before stopping the reaction
by addition of 100 µL 1 N H2SO4 to each well. Absorbance was measured with the help of ELISA plate
reader at 450 and 620 nm.
4.11. Inhibition of Endothelial Cell Proliferation by VEGFR1(D1-D3)-Fc
Angiogenic factors including VEGF can promote cell proliferation in endothelial cells. Here, the
inhibitory effect of the anti-angiogenic molecule, VEGFR1(D1–D3)-Fc, in inhibiting VEGF165-induced
proliferation of human umbilical vein endothelial cells (HUVEC) was studied to confirm its biological
activity. HUVEC (5000 cells per well) were seeded in wells of a 96-well microtitre plate in 100 µL assay
medium containing 2% serum. Neutralization mixes containing VEGF165 (25 ng/mL) alone and in
combination with different concentrations of VEGFR1(D1–D3)-Fc (5, 10, 50, 100, 150, 200, 250 ng/mL)
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were incubated at 37 ˝C in a 5% CO2 incubator for 3 h before being added to experimental wells
containing cells. The plate was incubated at 37 ˝C for 72 h after which cell proliferation was quantitated
by using the alamar blue method of detection. The fluorescence (relative fluorescence units, RFU) was
measured at an excitation wavelength of 544 nm and an emission wavelength of 590 nm using a BMG
Lab tech Polar star OPTIMA plate reader.
4.12. Inhibition of Endothelial Tube Formation by VEGFR1(D1-D3)-Fc
The ability of endothelial cells to form a three-dimensional capillary/tube-like network is
a specialized function of these cells [27]. Inhibition of angiogenesis can be assessed in vitro by the
inability of an angiogenesis inhibitor, such as VEGFR1(D1–D3)-Fc, to form such tubes in endothelial
cell lines. Matrigel (50 µL) was added to wells of a 96-well plate and then incubated at 37 ˝C for 1 h
to allow optimal well coating. Human umbilical vein endothelial cells (HUVEC), previously starved
overnight, were seeded at a density of 10,000 cells in 50 µL per well in matrigel-coated wells in medium
containing pre-incubated mix of VEGF165 at 50 ng/mL concentration and various concentrations of the
VEGFR1(D1–D3)-Fc protein (5, 25, 100, 250 µg/mL). Plates were incubated at 37 ˝C for 4–6 h in
a humidified 5% CO2 incubator after which, wells were viewed for tube formation at various
time-points with an inverted microscope under bright field illumination and images acquired and
processed with Image J software. An angiogenic parameter, namely total capillary length, per field,
was evaluated. Results scored from two random fields in duplicate wells were averaged.
5. Conclusions
Fc-fusion proteins have a bright future in biotherapeutic industry owing to their vast repertoire of
therapeutic targets, improved half-life and serum stability over monoclonal antibodies, application to
the broad range of diseases, considerable success in the number of products so far approved and global
sale values. Our recombinant Fc-fusion protein of interest, VEGFR1(D1–D3)-Fc, exhibits clipping in
mammalian cell culture. In the current study, several parameters were evaluated including the addition
of protease inhibitors in culture media, lowering of culture temperature and duration of culture, in a bid
to reduce proteolysis of the fusion protein. It was observed that proteolysis could be reduced to a large
extent by growing the cells in CDCHO media containing ferric citrate or protease inhibitor cocktail, as
well as lowering of culture incubation temperature from 37 to 30 ˝C. The purified protein containing
5% degraded low molecular weight species, was overall stable with properly folded secondary and
tertiary structures and had a strong affinity towards its biological ligands. In vitro bioassays using
human endothelial cells indicated that the protein was biologically active. Further, in vivo studies need
to be carried out in mice xenograft tumor models in order to assess the functional anti-tumor and
anti-angiogenic activities of this fusion protein. Hence, it can be concluded from these studies that the
protein, by virtue of its strong VEGF binding and inhibitory abilities, can be a promising therapeutic
approach in diseases where VEGF-induced angiogenesis and abnormal endothelial proliferation play
a key role.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/6/
913/s1.
Acknowledgments: The authors acknowledge the Deakin India Research Initiative (DIRI) program initiated
between Reliance Institute of Life Sciences, India and Deakin University, Australia. The authors gratefully
acknowledge Reliance Life Sciences Pvt. Ltd., Mumbai, India, for financial support of the project.
Author Contributions: Venkata Ramana and Sanjukta Chakrabarti conceived and designed the experiments;
Sanjukta Chakrabarti performed the experiments; Sanjukta Chakrabarti, Venkata Ramana, Colin J. Barrow, Jagat R.
Kanwar and Rupinder K. Kanwar analyzed the data; Sanjukta Chakrabarti wrote the paper. Rupinder K. Kanwar
and Jagat R. Kanwar proof read the manuscript and gave valuable inputs.
Conflicts of Interest: The authors declare no conflicts of interest. Reliance Life Sciences Pvt. Ltd., Mumbai, India,
funded the design of the study as well as collection, analyses and interpretation of data and in the writing of the
manuscript. Both Reliance Life Sciences Pvt. Ltd. and Deakin University had a role in the decision to publish
the results.
Int. J. Mol. Sci. 2016, 17, 913 21 of 22
References
1. Huang, C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology. Curr. Opin. Biotechnol.
2009, 20, 692–699. [CrossRef] [PubMed]
2. Kontermann, R.E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 2011,
22, 868–876. [CrossRef] [PubMed]
3. Carter, P.J. Introduction to current and future protein therapeutics: A protein engineering perspective.
Exp. Cell Res. 2011, 317, 1261–1269. [CrossRef] [PubMed]
4. Dimitrov, D. Therapeutic Proteins; Voynov, V., Caravella, J.A., Eds.; Humana Press: New York, NY, USA, 2012;
pp. 1–26.
5. Dorai, H.; Ganguly, S. Mammalian cell-produced therapeutic proteins: Heterogeneity derived from protein
degradation. Curr. Opin. Biotechnol. 2014, 30, 198–204. [CrossRef] [PubMed]
6. Beck, A.; Reichert, J.M. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies.
MAbs 2011, 3, 415–416. [CrossRef] [PubMed]
7. Rob, A.S. What’s fueling the biotech engine-2012 to 2013. Nat. Biotechnol. 2014, 32, 32.
8. Schmidt, S.R. Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges; John Wiley & Sons:
Hoboken, NJ, USA, 2013.
9. Enfors, S.-O. Control of in vivo proteolysis in the production of recombinant proteins. Trends Biotechnol. 1992,
10, 310–315. [CrossRef]
10. Dorai, H.; Nemeth, J.F.; Cammaart, E.; Wang, Y.; Tang, Q.M.; Magill, A.; Lewis, M.J.; Raju, T.S.; Picha, K.;
O’Neil, K.; et al. Development of mammalian production cell lines expressing CNTO736, a glucagon like
peptide-1-MIMETIBODYTM: Factors that influence productivity and product quality. Biotechnol. Bioeng.
2009, 103, 162–176. [CrossRef] [PubMed]
11. Robert, F.; Bierau, H.; Rossi, M.; Agugiaro, D.; Soranzo, T.; Broly, H.; Mitchell-Logean, C. Degradation of
an Fc-fusion recombinant protein by host cell proteases: Identification of a CHO cathepsin D protease.
Biotechnol. Bioeng. 2009, 104, 1132–1141. [CrossRef] [PubMed]
12. Huang, Y.M.; Hu, W.; Rustandi, E.; Chang, K.; Yusuf-Makagiansar, H.; Ryll, T. Maximizing productivity of
CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing
equipment. Biotechnol. Prog. 2010, 26, 1400–1410. [CrossRef] [PubMed]
13. Galbraith, D.J.; Tait, A.S.; Racher, A.J.; Birch, J.R.; James, D.C. Control of culture environment for improved
polyethylenimine-mediated transient production of recombinant monoclonal antibodies by CHO cells.
Biotechnol. Prog. 2006, 22, 753–762. [CrossRef] [PubMed]
14. Zhu, J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol. Adv. 2012, 30,
1158–1170. [CrossRef] [PubMed]
15. Sandberg, H.; Lütkemeyer, D.; Kuprin, S.; Wrangel, M.; Almstedt, A.; Persson, P.; Ek, V.;
Mikaelsson, M. Mapping and partial characterization of proteases expressed by a CHO production cell line.
Biotechnol. Bioeng. 2006, 95, 961–971. [CrossRef] [PubMed]
16. Satoh, M.; Hosoi, S.; Sato, S. Chinese hamster ovary cells continuously secrete a cysteine endopeptidase.
In Vitro Cell. Dev. Biol. 1990, 26, 1101–1104. [CrossRef] [PubMed]
17. Clincke, M.-F.; Guedon, E.; Yen, F.T.; Ogier, V.; Goergen, J.-L. Characterization of metalloprotease and serine
protease activities in batch CHO cell cultures: Control of human recombinant IFN-γ proteolysis by addition
of iron citrate. BMC Proc. 2011, 5, P115. [CrossRef] [PubMed]
18. Caprioli, R.M.; Farmer, T.B.; Gile, J. Molecular imaging of biological samples: Localization of peptides and
proteins using MALDI-TOF MS. Anal. Chem. 1997, 69, 4751–4760. [CrossRef] [PubMed]
19. Burstein, E.; Vedenkina, N.; Ivkova, M. Fluorescence and the location of tryptophan residues in protein
molecules. Photochem. Photobiol. 1973, 18, 263–279. [CrossRef] [PubMed]
20. Whitmore, L.; Wallace, B.A. Protein secondary structure analyses from circular dichroism spectroscopy:
Methods and reference databases. Biopolymers 2008, 89, 392–400. [CrossRef] [PubMed]
21. Micsonai, A.; Wien, F.; Kernya, L.; Lee, Y.H.; Goto, Y.; Réfrégiers, M.; Kardos, J. Accurate secondary structure
prediction and fold recognition for circular dichroism spectroscopy. Proc. Natl. Acad. Sci. USA 2015, 112,
E3095–E3103. [CrossRef] [PubMed]
22. Davies, S.L.; Lovelady, C.S.; Grainger, R.K.; Racher, A.J.; Young, R.J.; James, D.C. Functional heterogeneity
and heritability in CHO cell populations. Biotechnol. Bioeng. 2013, 110, 260–274. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 913 22 of 22
23. Raju, T.S.; Scallon, B.J. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by
papain. Biochem. Biophys. Res. Commun. 2006, 341, 797–803. [CrossRef] [PubMed]
24. Rosenmund, A.; Haeberli, A.; Straub, P. Blood coagulation and acute iron toxicity. Reversible iron-induced
inactivation of serine proteases in vitro. J. Aborat. Clin. Med. 1984, 103, 524–533.
25. Hwang, S.-J.; Yoon, S.K.; Koh, G.Y.; Lee, G.M. Effects of culture temperature and pH on
flag-tagged COMP angiopoietin-1 (FCA1) production from recombinant CHO cells: FCA1 aggregation.
Appl. Microbiol. Biotechnol. 2011, 91, 305–315. [CrossRef] [PubMed]
26. Yoon, S.K.; Song, J.Y.; Lee, G.M. Effect of low culture temperature on specific productivity, transcription level,
and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol. Bioeng. 2003, 82, 289–298.
[CrossRef] [PubMed]
27. Arnaoutova, I.; George, J.; Kleinman, H.K.; Benton, G. The endothelial cell tube formation assay on basement
membrane turns 20: State of the science and the art. Angiogenesis 2009, 12, 267–274. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
